Organisation paid for research Program year 2023 Source: CMS Open Payments

Future Search Trials

Neither a doctor nor a teaching hospital

Research payments

$134,520

20 payments

Through program year 2023, Future Search Trials is reported as receiving $134,520 in research payments, across 20 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$18,384	3
2022	Research	$57,113	6
2021	Research	$2,367	2
2020	Research	$876	2
2019	Research	$55,780	7

Breakdown

Who paid Research payments · program years 2019–2023

ACADIA Pharmaceuticals Inc $75,497 9 payments
Allergan Inc. $59,023 11 payments

Studies the money was for Research payments · program years 2019–2023

Acp-044-005 $65,113 6 payments
A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $53,780 6 payments
Acp-044-005 $10,384 3 payments
A Multicenter, Randomized, Open Label Extension Study to Evaluate the Long Term Safety and Toloerability of Oral Ubrogepant in the Acute Treatment of Migraine With Or Without Aura $2,000 1 payment
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine Who Have Previously Failed 2 $1,392 1 payment
A Phase 3, Multicenter, Open-Label 52-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Chronic Or Episodic Migraine $975 1 payment
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Treatment of Migraine When Adminstered During the Premonitory Phase $876 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.